Fair Value Measurement (Details) - Schedule of Company’s Liabilities at Fair Value on a Recurring Basis - USD ($)	Sep. 30, 2025	Jun. 30, 2025
Liabilities:
Accompanying warrants liability	$ 8,092,218	$ 3,701,492
Fair Value, Recurring [Member]
Liabilities:
Contingent consideration	1,156,912	1,169,675
Accompanying warrants liability	8,092,218	3,701,492
Total liabilities measured at fair value	9,249,130	4,871,167
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Liabilities:
Contingent consideration
Accompanying warrants liability
Total liabilities measured at fair value
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Liabilities:
Contingent consideration
Accompanying warrants liability
Total liabilities measured at fair value
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Liabilities:
Contingent consideration	1,156,912	1,169,675
Accompanying warrants liability	8,092,218	3,701,492
Total liabilities measured at fair value	$ 9,249,130	$ 4,871,167

Neuphoria Therapeutics Inc. 10-Q